Using SubMap analysis, we mapped the expression profiles of three immune subtypes (C1, C2, and C3) with another published cohort involving 47 melanoma patients who were treated with a PD-1 or CTLA-4 immune checkpoint inhibitor. This evidence concerns the gene CTLA4 and melanoma.